Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

#3460

Introduction: Clinical trial data show prolonged progression-free survival (PFS) with LAN in metastatic enteropancreatic NET; real-world data may demonstrate effectiveness in routine care.

Aim(s): Primary objective: Estimate PFS rate 24 months after starting LAN; secondary objectives: Describe change in quality of life (QoL) 24 months after starting LAN and patient satisfaction with treatment at 12 and 24 months after LAN.

Materials and methods: Non-interventional multicenter study planned in 196 patients with functioning or non-functioning G1/G2 unresectable, locally-advanced or metastatic panNET already on LAN for 3–12 months in Spain and Portugal (NCT03947762). Data were collected retrospectively from diagnosis and prospectively at 6-monthly visits up to 24 months, study withdrawal, disease progression or death. Kaplan Meier curves were used to estimate PFS rate. QoL was assessed with QLQ-C30 and QLQ-GINET21 questionnaires, and treatment satisfaction with TSQM-9 (scores /100).

Conference:

Presenting Author: Alonso T

Authors: Alonso-Gordoa T, Capdevila J, González E, Teulé A, Anido U,

Keywords: net, pancreas, lanreotide, clinical practice,